SLPI Antibody

SLPI Antibody: Secretory leukocyte protease inhibitor (SLPI) is produced at mucosal surfaces, primarily the upper respiratory tract and is thought to play an important role in the antiprotease defense mechanism of the lung. SLPI forms inhibitory complexes with numerous proteolytic enzymes such as neutrophil elastase, and has been shown to possess anti-inflammatory, anti-viral, and antibacterial activities. Its expression in oral epithelial cells is stimulated by HIV-1 gp120, suggesting that SLPI is a component of the oral mucosal response to HIV-1. In peripheral blood monocytes, SLPI can inhibit NF-κ B activation by inhibiting Iκ B degradation in the cytoplasm and competing for NF-κ B binding sites in the nucleus. This attenuation of the inflammatory response may also act to suppress liver metastases and other cancer cell invasions, but promote blood-borne metastasis via an invasion-independent pathway.

SLPI antibody can be stored at 4˚ C for three months and -20˚ C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Abe T, Kobayashi N, Yoshimura K, et al. Expression of the secretory leukoprotease inhibitor gene in epithelial cells. J. Clin. Invest.1991; 87:2207-15.

Hiemstra PS, Fernie-King BA, McMichael J, et al. Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapies. Curr. Pharm. Des.2004; 10:2891-905.

Jana NK, Gray LR and Shugars DC. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SPLI) in oral epithelial cells: a role for SLPI in innate mucosal immunity. J. Virol.2005; 79:6432-40.

Taggart CC, Cryan S-A, Weldon S, et al. Secretory leucoprotease inhibitor binds to NF-kB binding sites in monocytes and inhibits p65 binding. J. Exp. Med.2005; 202:1659-68.